Literature DB >> 12395079

The Arctic mutation interferes with processing of the amyloid precursor protein.

Charlotte Stenh1, Camilla Nilsberth, Josefin Hammarbäck, Benita Engvall, Jan Näslund, Lars Lannfelt.   

Abstract

The Arctic amyloid precursor protein (APP) Alzheimer mutation, is located inside the beta-amyloid (Abeta) domain. Here, hybrid APP mutants containing both the Swedish and the Arctic APP mutations were investigated. ELISA measurements of cell media showed decreased levels of both Abeta40 and Abeta42. Similar results were obtained for the Dutch and Italian mutations, whereas the Flemish mutation displayed increased amounts of Abeta40 and Abeta42. Immunoprecipitation studies revealed increased Abeta40/p3 and Abeta42/p3 ratios for the Arctic mutation. These results were further verified by quantification revealing decreased levels of alphaAPPs accompanied by increased betaAPPs levels in the media. Thus, the pathogenic effects of the Arctic mutation may not only be due to the changed properties of the peptide but also altered processing of Arctic APP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395079     DOI: 10.1097/00001756-200210280-00005

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  8 in total

1.  Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease.

Authors:  Hans Basun; Nenad Bogdanovic; Martin Ingelsson; Ove Almkvist; Jan Näslund; Karin Axelman; Thomas D Bird; David Nochlin; Gerard D Schellenberg; Lars-Olof Wahlund; Lars Lannfelt
Journal:  Arch Neurol       Date:  2008-04

2.  Novel APP/Aβ mutation K16N produces highly toxic heteromeric Aβ oligomers.

Authors:  Daniela Kaden; Anja Harmeier; Christoph Weise; Lisa M Munter; Veit Althoff; Benjamin R Rost; Peter W Hildebrand; Dietmar Schmitz; Michael Schaefer; Rudi Lurz; Sabine Skodda; Raina Yamamoto; Sönke Arlt; Ulrich Finckh; Gerd Multhaup
Journal:  EMBO Mol Med       Date:  2012-04-19       Impact factor: 12.137

3.  Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation.

Authors:  L Kulic; J McAfoose; T Welt; C Tackenberg; C Späni; F Wirth; V Finder; U Konietzko; M Giese; A Eckert; K Noriaki; T Shimizu; K Murakami; K Irie; S Rasool; C Glabe; C Hock; R M Nitsch
Journal:  Transl Psychiatry       Date:  2012-11-13       Impact factor: 6.222

4.  Cerebral amyloid angiopathy: a systematic review.

Authors:  Alessandro Biffi; Steven M Greenberg
Journal:  J Clin Neurol       Date:  2011-03-31       Impact factor: 3.077

5.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

Authors:  Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong
Journal:  Alzheimers Res Ther       Date:  2011-01-06       Impact factor: 6.982

Review 6.  Insights into Alzheimer disease pathogenesis from studies in transgenic animal models.

Authors:  Evelin L Schaeffer; Micheli Figueiro; Wagner F Gattaz
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network.

Authors:  Celeste M Karch; Damián Hernández; Jen-Chyong Wang; Jacob Marsh; Alex W Hewitt; Simon Hsu; Joanne Norton; Denise Levitch; Tamara Donahue; Wendy Sigurdson; Bernardino Ghetti; Martin Farlow; Jasmeer Chhatwal; Sarah Berman; Carlos Cruchaga; John C Morris; Randall J Bateman; Alice Pébay; Alison M Goate
Journal:  Alzheimers Res Ther       Date:  2018-07-25       Impact factor: 6.982

8.  Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.

Authors:  Erik C B Johnson; Kaitlyn Ho; Gui-Qiu Yu; Melanie Das; Pascal E Sanchez; Biljana Djukic; Isabel Lopez; Xinxing Yu; Michael Gill; Weiping Zhang; Jeanne T Paz; Jorge J Palop; Lennart Mucke
Journal:  Mol Neurodegener       Date:  2020-09-14       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.